EPS for Adamis Pharmaceuticals Corporation (ADMP) Expected At $-0.15

March 14, 2018 - By Richard Conner

 EPS for Adamis Pharmaceuticals Corporation (ADMP) Expected At $ 0.15

Analysts expect Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) to report $-0.15 EPS on March, 29. The stock decreased 2.63% or $0.1 during the last trading session, reaching $3.7. About 745,153 shares traded. Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has declined 52.09% since March 15, 2017 and is downtrending. It has underperformed by 68.79% the S&P500.

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Ratings Coverage

Among 4 analysts covering Adamis Pharma (NASDAQ:ADMP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adamis Pharma had 9 analyst reports since December 1, 2015 according to SRatingsIntel. The rating was maintained by Raymond James on Monday, December 4 with “Buy”. On Monday, June 12 the stock rating was maintained by Maxim Group with “Buy”. The rating was initiated by Raymond James on Tuesday, September 12 with “Buy”. The firm has “Buy” rating given on Thursday, July 21 by Maxim Group. The stock has “Buy” rating by Maxim Group on Monday, August 21. The company was initiated on Tuesday, December 1 by Maxim Group.

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company has market cap of $123.53 million. The companyÂ’s specialty pharmaceutical product candidates comprise Epinephrine Injection pre-filled syringe for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of albuterol (APC-2000) and fluticasone (APC-4000) for the treatment of bronchospasm and asthma; and beclomethasone (APC-1000), a metered dose inhaler product for the asthma, as well as APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease. It currently has negative earnings. It also operates a 503B drug outsourcing facility that provides prescription compounded medications to patients, physician clinics, hospitals, surgery centers, and other clients in the United States.

More notable recent Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) news were published by: Seekingalpha.com which released: “It Is Finally Time To Get Into Adamis Pharmaceuticals” on March 01, 2018, also Marketwatch.com with their article: “Adamis Pharmaceuticals Corp.” published on December 03, 2015, Seekingalpha.com published: “Adamis Pharmaceuticals: A Rocket Counting Down To Lift-Off” on October 25, 2017. More interesting news about Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) were released by: Seekingalpha.com and their article: “Can Adamis Bleed Mylan Dry?” published on December 13, 2017 as well as Seekingalpha.com‘s news article titled: “Adamis Pharmaceuticals: January Thesis Update” with publication date: January 25, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.